



# NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 24 Oct 2022 (#40)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

**To prepare an application can take 4-18 months, depending on many factors:**

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Important Notices

**Gearing Up for Transition to FORMS-H Application Forms:** As [announced](#) over the summer, NIH requires the use of updated application forms (FORMS-H) for due dates on or after January 25, 2023. We will begin adding FORMS-H application packages to active funding opportunity announcements and FORMS-H application form instructions to the [How to Apply – Application Guide](#) page as early as October 25 to prepare for the transition.

The intended due date for your application determines the correct form version to use.

- DO use FORMS-G form version for application due dates on or before January 24, 2023
- DO use FORMS-H form version for application due dates on or after January 25, 2023
- DO NOT use FORMS-H too early or FORMS-G too late

## Notices of Special Interest (NOSI)

**[NOT-CA-23-004](#) Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers.** The purpose of this Notice of Special Interest (NOSI) is to encourage research studies leveraging partnerships between biomarker technology developers with assays for early cancer detection, and population-based researchers, including cohort and biorepository researchers. Proposals that facilitate early cancer biomarker assay development, verification, qualification, and validation utilizing statistically powered retrospective cohorts and/or through prospective studies in the appropriate populations with a sound study design are responsive to this NOSI. This notice applies to due dates on or after January 5, 2023, and subsequent receipt dates through July 02, 2025. Submit applications for this initiative using one of the funding opportunity announcements (FOAs) in the announcement.

**[NOT-DA-22-084](#) Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NIDA Populations of Interest.** This notice informs applicants of an expansion to the [NOT-HD-22-038](#) "Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest" to include research priority areas for the National Institute on Drug Abuse (NIDA).

The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to announce that research on the effects of:

- emerging and evolving public health crises; and/or
- policy changes

on the health, development, and well-being of populations of interest to the NIDA is of high program priority. The NIDA populations of interest include neonates, infants, children, adolescents, young adults, adults, and older adults, people using or misusing substances, people with substance use disorders, as well as the families of these individuals. The NIDA supports research on the impact of policy in understanding and addressing substance use risk and behavior across the life span. For information on the NIDA Strategic Goals and Mission, see <https://nida.nih.gov/about-nida/strategic-plan/nidas-mission>. Research focused on outcomes in specific locations are also permitted if the results can be generalized to the United States overall, a large segment of the U.S. population, a major U.S. subpopulation, or a health disparities population. Applicants are strongly encouraged to discuss potential applications with the Scientific/Research Contact listed below before submitting their application. This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026. Submit applications for this initiative using one of the funding opportunity announcements (FOAs) in the announcement.

## Funding Opportunity Announcements (FOA)

### 1. National Center for Medical Rehabilitation Research (NCMRR) Early Career Research Award (R03 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-029](#)

**Type:** R03

**Application Due Date:** March 28, 2023; March 28, 2024; March 28, 2025. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** The National Center for Medical Rehabilitation Research (NCMRR) Early Career Research (ECR) Award (R03) is intended to support both basic and clinical research from rehabilitation scientists who are establishing independent research careers. The research must be focused on one or more of the areas within the mission of NCMRR: Applicants are encouraged to refer to the NIH Research Plan on Rehabilitation for strategic priorities (<https://www.nichd.nih.gov/newsroom/news/110121-NIH-rehab-plan>). The NCMRR ECR Award R03 grant mechanism supports various types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new technology. Irrespective of the type of project, the intent of the NCMRR ECR Award R03 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.

**Budget:** The combined budget for direct costs for the entire project period may not exceed \$200,000. No more than \$100,000 in direct costs may be requested in any single year. The scope of the proposed project should determine the project period. The maximum period of support is 2 years.

### 2. Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-DA-24-007](#)

**Type:**

**Application Due Date:** August 09, 2023; August 09, 2024; August 07, 2025. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** Avenir means future in French, and this Avenir Award Program looks toward the future by supporting early stage investigators proposing highly innovative research in the area of chemistry and pharmacology of substance use disorders and

addiction. The purpose of this award is to support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field.

**Budget:** National Institute on Drug Abuse ([NIDA](#)) intends to commit \$3,000,000 in each fiscal year FY 2024 - FY 2026 to fund 5-6 awards each year. Application budgets are limited to \$300,000 in Direct Costs each year for up to five years, plus applicable Facilities and Administrative (F&A) costs to be determined at the time of award. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 3. Toward Elucidating Mechanisms of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-DK-22-039](#)

**Type:** R01

**Application Due Date:** March 15, 2023. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) seeks to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will comprehensively interrogate fundamental biological mechanisms underlying HIV-associated comorbidities, co-infections, and complications relevant to the mission of the NIDDK and advance progress toward preventing or alleviating them.

**Budget:** National Institute of Diabetes and Digestive and Kidney Diseases ([NIDDK](#)) intends to commit \$2,000,000 in FY 2024 to fund 2-3 awards. Application budgets are limited to \$500,000 direct costs per year and should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences  
K<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Division for Research Development (DRD)  
Stellenbosch Campus  
2041 Krotoa Building, Ryneveld Street  
Enquiries: *Lizel*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105